Dutasteride: Novel milestones in prostate cancer chemoprevention

Drugs of Today

Volumn 47, Issue 2, 2011, Pages 135-144

  Rove, K O ^a   Crawford, E David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE; TUMOR MARKER;

CANCER RISK; CHEMOPROPHYLAXIS; DRUG EFFICACY; ETHNIC DIFFERENCE; GYNECOMASTIA; HUMAN; LIBIDO; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SEX DIFFERENTIATION; SIDE EFFECT; TRANSRECTAL ULTRASONOGRAPHY;

5-ALPHA REDUCTASE INHIBITORS; ANIMALS; ANTICARCINOGENIC AGENTS; AZASTEROIDS; DIHYDROTESTOSTERONE; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 79955886896     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.2.1561069     Document Type: Review

References (68)

1. Jemal, A., Siegel, R., Xu, J., Ward, E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5): 277-300.
2. Ung, J.O., Richie, J.P., Chen, M.H., Renshaw, A.A., D'Amico, A.V. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002, 60(3): 458-63. (Pubitemid 35292173)
3. Thompson, I.M., Goodman, P.J., Tangen, C.M. et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349(3): 215-24. (Pubitemid 36859473)
4. Andriole, G.L., Bostwick, D.G., Brawley, O.W. et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362(13): 1192-202.
5. Draisma, G., Etzioni, R., Tsodikov, A. et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009, 101(6): 374-83.
6. Etzioni, R., Penson, D.F., Legler, J.M., di Tommaso, D., Boer, R., Gann, P.H., Feuer, E.J. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002, 94(13): 981-90. (Pubitemid 34814727)
7. Altekruse, S.F., Kosary, C.L., Krapcho, M. et al. SEER Cancer Statistics Review, 1975-2007. National Cancer Institute. Bethesda, MD. http://seer.cancer. gov/csr/1975-2007/. Accessed October 15, 2010.
8. Barry, M.J. Screening for prostate cancer - the controversy that refuses to die. N Engl J Med 2009, 360(13): 1351-4.
9. Crawford, E.D., Black, L., Eaddy, M., Kruep, E.J. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis 2010, 13(2): 162-7.
10. Schroder, F.H., Hugosson, J., Roobol, M.J. et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360(13): 1320-8.
11. US Preventive Services Task Force. Screening for Prostate Cancer: Recommendation Statement. http://www.uspreventiveservicestaskforce.org/uspstf08/ prostate/prostaters.htm. Accessed October 15, 2010.
12. Levin, B., Lieberman, D.A., McFarland, B. et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008, 58(3): 130-60.
13. Screening for prostate cancer. American College of Physicians. Ann Intern Med 1997, 126(6): 480-4.
14. Huggins, C., Hodges, C.V. Studies on prostate cancer. I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1: 293-7.
15. Wilbert, D.M., Griffin, J.E., Wilson, J.D. Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab 1983, 56(1): 113-20. (Pubitemid 13212316)
16. Marks, L.S. 5alpha-reductase: history and clinical importance. Rev Urol 2004, 6 Suppl 9: S11-21.
17. Andersson, S., Berman, D.M., Jenkins, E.P., Russell, D.W. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 1991, 354(6349): 159-61. (Pubitemid 21896802)
18. Imperato-McGinley, J., Guerrero, L., Gautier, T., Peterson, R.E. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974, 186(4170): 1213-5.
19. Walsh, P.C. Urological survey: Urological oncology: Prostate cancer. J Urol 2010, 184(5): 1354-7.
20. Ross, R.K., Bernstein, L., Lobo, R.A., Shimizu, H., Stanczyk, F.Z., Pike, M.C., Henderson, B.E. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992, 339(8798): 887-9.
21. Ntais, C., Polycarpou, A., Tsatsoulis, A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 2003, 149(6): 469-77. (Pubitemid 38054690)
22. Imperato-McGinley, J., Zhu, Y.S. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 2002, 198(1-2): 51-9. (Pubitemid 36169934)
23. Hsing, A.W. Hormones and prostate cancer: what's next? Epidemiol Rev 2001, 23(1): 42-58.
24. Thomas, L.N., Douglas, R.C., Vessey, J.P. et al. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 2003, 170(5): 2019-25. (Pubitemid 37255000)
25. Thomas, L.N., Douglas, R.C., Lazier, C.B., Too, C.K., Rittmaster, R.S., Tindall, D.J. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008, 53(2): 244-52. (Pubitemid 350296595)
26. Thomas, L.N., Lazier, C.B., Gupta, R., Norman, R.W., Troyer, D.A., O'Brien, S.P., Rittmaster, R.S. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005, 63(3): 231-9. (Pubitemid 40571057)
27. Uemura, M., Tamura, K., Chung, S., Honma, S., Okuyama, A., Nakamura, Y., Nakagawa, H. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008, 99(1): 81-6. (Pubitemid 350239034)
28. Mitsiades, N., Schultz, N., Taylor, B.S., et al. Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): 5002.
29. Cantagrel, V., Lefeber, D.J., Ng, B.G. et al. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 2010, 142(2): 203-17.
30. Tindall, D.J., Rittmaster, R.S. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008, 179(4): 1235-42.
31. Andriole, G., Bostwick, D., Civantos, F., Epstein, J., Lucia, M.S., McConnell, J., Roehrborn, C.G. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol 2005, 174(6): 2098-104. (Pubitemid 41611745)
32. Rittmaster, R.S. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab 2008, 22(2): 389-402. (Pubitemid 351611959)
33. Clark, R.V., Hermann, D.J., Cunningham, G.R., Wilson, T.H., Morrill, B.B., Hobbs, S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004, 89(5): 2179-84. (Pubitemid 38619850)
34. Gormley, G.J., Stoner, E., Bruskewitz, R.C. et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992, 327(17): 1185-91.
35. Andriole, G.L., Guess, H.A., Epstein, J.I. et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998, 52(2): 195-201.
36. Andriole, G.L., Roehrborn, C., Schulman, C., Slawin, K.M., Somerville, M., Rittmaster, R.S. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004, 64(3): 537-41.
37. Roehrborn, C.G., Boyle, P., Nickel, J.C., Hoefner, K., Andriole, G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60(3): 434-41. (Pubitemid 35292169)
38. Lippman, S.M., Goodman, P.J., Klein, E.A. et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005, 97(2): 94-102. (Pubitemid 40277089)
39. Lippman, S.M., Klein, E.A., Goodman, P.J. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301(1): 39-51.
40. Lucia, M.S., Epstein, J.I., Goodman, P.J. et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007, 99(18): 1375-83. (Pubitemid 351767184)
41. Thompson, I.M., Lucia, M.S., Redman, M.W. et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol 2007, 178(1): 107-9.
42. Cohen, Y.C., Liu, K.S., Heyden, N.L., Carides, A.D., Anderson, K.M., Daifotis, A.G., Gann, P.H. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007, 99(18): 1366-74. (Pubitemid 351767189)
43. Kulkarni, G.S., Al-Azab, R., Lockwood, G. et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 2006, 175(2): 505-9. (Pubitemid 43067339)
44. Redman, M.W., Tangen, C.M., Goodman, P.J., Lucia, M.S., Coltman, C.A., Jr., Thompson, I.M. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 2008, 1(3): 174-81.
45. Pinsky, P., Parnes, H., Ford, L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila) 2008, 1(3): 182-6.
46. Canby-Hagino, E., Hernandez, J., Brand, T.C., Thompson, I. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol 2007, 51(1): 27-33. (Pubitemid 44821534)
47. Roehrborn, C.G., Lotan, Y., Tubaro, A., de Nunzio, C. Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible. Eur Urol 2006, 49(2): 396-400.
48. Goetzl, M.A., Holzbeierlein, J.M. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice. Nat Clin Pract Urol 2006, 3(8): 422-9. (Pubitemid 44226919)
49. Lucia, S. Do 5 alpha-reductase inhibitors alter prostate cancer detection and what are the implications? Eur Urol 2006, 5(Suppl.): 752-7.
50. Andriole, G., Bostwick, D., Brawley, O. et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004, 172(4 Pt 1): 1314-7. (Pubitemid 39249705)
51. Parekh, D.J., Ankerst, D.P., Higgins, B.A. et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 2006, 68(6): 1152-5. (Pubitemid 44880388)
52. Schroder, F.H., Roobol, M.J., Andriole, G.L., Fleshner, N. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol 2009, 181(1): 69-74.
53. Hughes, A., O'Donnell, C., Tandberg, D.J., Crawford, E.D. Use of a 1.5 PSA threshold to identify increased risk for prostate cancer in a screening population. J Urol [Annu Meet Am Urol Assoc (AUA) (May 29-June 3, San Francisco) 2010] 2010, 183(4, Suppl.): Abst.
54. Choo, R., Danjoux, C., Morton, G. et al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer? Prostate 2007, 67(15): 1614-20.
55. Walsh, P.C. Chemoprevention of prostate cancer. N Engl J Med 2010, 362(13): 1237-8.
56. Andriole, G.L., Crawford, E.D., Grubb, R.L., 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360(13): 1310-9.
57. Murtola, T.J., Tammela, T.L., Maattanen, L., Ala-Opas, M., Stenman, U.H., Auvinen, A. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer 2009, 101(5): 843-8.
58. Jansen, F.H., van Schaik, R.H., Kurstjens, J. et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010, 57(6): 921-7.
59. Demichelis, F., Fall, K., Perner, S. et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007, 26(31): 4596-9. (Pubitemid 47037039)
60. Johnson, T.R., Koul, S., Kumar, B. et al. Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF. Mol Cancer 2010, 9: 148.
61. Kramer, B.S., Hagerty, K.L., Justman, S. et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 2009, 27(9): 1502-16.
62. Wilt, T.J., MacDonald, R., Hagerty, K., Schellhammer, P., Kramer, B.S. Five-alpha-reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev 2008(2): CD007091.
63. Fleshner, N., Gomella, L.G., Cookson, M.S. et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007, 28(6): 763-9. (Pubitemid 47499254)
64. Barqawi, A.B., O'Donnell, C.I., Siomos, V.J., Hou, A.H. The effect of short-term dutasteride intake in early-stage prostate cancer: analysis of 148 patients who underwent three-dimensional prostate mapping biopsy. Urology 2010, 76(5): 1067-71.
65. Avodart reviewed by FDA advisory committee for prostate cancer risk reduction [news release]. GlaxoSmithKline, December 1, 2010. Accessed January 28, 2011.
66. GSK receives FDA Complete Response letter for Avodart for prostate cancer risk reduction supplemental indication [news release]. GlaxoSmithKline, January 26, 2011. Accessed January 28, 2011.
67. Etzioni, R.D., Howlader, N., Shaw, P.A., Ankerst, D.P., Penson, D.F., Goodman, P.J., Thompson, I.M. Long-term effects of finasteride on prostate specific antigen levels: Results from the Prostate Cancer Prevention Trial. J Urol 2005, 174(3): 877-81. (Pubitemid 41140621)
68. Thompson, I.M., Ankerst, D.P., Chi, C. et al. Prediction of prostate cancer for patients receiving finasteride: Results from the prostate cancer prevention trial. J Clin Oncol 2007, 25(21): 3076-81. (Pubitemid 47218054)